Slingshot members are tracking this event:
On August 10th, FDA to give PDUFA decision on Amgen's (AMGN) BLINCYTO (blinatumomab) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)
Slingshot Insights Explained
Jul 11, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Acute Lymphoblastic Leukemia, Blincyto® (blinatumomab), Pdufa, Phase 3 Tower Study